Sign up
Pharma Capital
EPIC: ARECO
Market: PRIVATE-UK
Sector: Pharma & Biotech
Website: arecor.com

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform.

Arecor is leveraging this platform to (i) develop a portfolio of proprietary products for diabetes care and (ii) deliver superior reformulations of its partners proprietary products.

Arecor

arecor.com

Interactive graph

col 3
col 4
col 5
col 6

Arecor Snapshot

Management

Sarah Howell, Ph.D., Chief Executive Officer


Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.

Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.
 

Jan Jezek, Ph.D., Chief Scientific Officer

Jan is a biochemist with a strong background in physical chemistry and the principal inventor of the core protein stabilisation technologies. Currently he is responsible at Arecor for R&D activities, platform development and IP strategy. He played a critical role in the development of stabilising technologies for commercially important therapeutic proteins and vaccines that form the core of Arecor business.
Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.

Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).


David Gerring, Director of Development

David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.
He is currently Director of Development and operations at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
 

Fiona Lawrence, Director of Project Management

Fiona is a pharmaceutical research and development professional and is currently Director of Project Management at Arecor, where she has responsibility for driving the clinical development of Arecor’s proprietary products’ portfolio.
She has broad expertise and experience stemming from work across different organisations in the biotech/pharma, public and not-for-profit/charitable sectors. Previously, she was Director of Research and Clinical Development at Duchenne UK with responsibility for developing the research strategy for the charity. She spent five years at BioMarin and Prosensa in Leiden, working as Senior Clinical Research Manager and four years as Commercial Trials Manager at Cambridge University Hospitals.

Fiona holds an MSc in Pharmaceutical Medicine from the University of Surrey and a BSc in Pharmacology from the University of Bath.


Laura Ciccolini, Ph.D., Director of Business Development & Licensing

Laura joined Arecor in 2018 as Director of Business Development. Coming from a background in Engineering, she has gained international experience across a number of business functions in the pharmaceutical, biotechnology and engineering/technology industries. She is multi-lingual and has built and trained successful teams, developed products and services, and managed complex programmes on a global scale, enabling expansion of businesses across markets.

Her most recent experience includes acting as Commercial Director at Bedrock Healthcare Communications Ltd, to provide medical communications, education and strategic counsel to the pharma and biopharma industries. Prior to that, she was Commercial Director and Member of the Executive Board at Biopharma Technology Limited, part of the Biopharma Group, a CRO delivering R&D services and production in lyophilisation to the pharma/biopharma and other industries. 
She has also held senior roles at SAFC Pharma and Pharmorphix of Sigma Aldrich in Cambridge and at Cancer Research UK in London.

Laura holds both a Ph.D. and an M.Eng Honours Degree in Biochemical Engineering from University College London, University of London and received awards from CellTech, IChemE for work in biochemical engineering, as well as being Dean Listed by the UCL Engineering Faculty.

Board of Directors

Sarah Howell, Ph.D., Chief Executive Officer

Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.
Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

Andrew J M Richards, Ph.D., CBE (Chairman)

Andy is an established biotechnology entrepreneur and investor with broad experience from the UK biotechnology sector in research, drug development, commercial deals and scaling up companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, and a director of Silence Therapeutics plc, Sensiia Ltd, and Ieso Digital Health Ltd. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial arm of Cancer Research UK).
Andy is a Cambridge graduate with a Ph.D. in enzyme chemistry and was a founder of Chiroscience in 1992 and an Executive Director through to the Celltech deal in 1999. Andy has a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd.

Sam Fazeli, Ph.D., Non-Executive Director

Sam has served as a member of our Board of Directors since September 2017 and he brings over nineteen years of experience of conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.
Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys. He received a first degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Andrew Lane, MA

Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University. He is a founding Director of Unilever Ventures which focuses on investments in Home and Personal Care Technology.
He has been involved as a Director in the set-up and development of three other life science businesses (BAC BV, Pharmakodex Ltd, and Insense Ltd).

Alan E Smith, Ph.D., FRS, CBE

Alan is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the vice president and scientific director of Integrated Genetics, a MA start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of: The Cancer Research Institute in Cambridge UK; Pharnext – a start-up genomics company in Paris, France; and ImmuneXcite – a start-up immunology company, in Lexington MA. He is on the Board of Directors of Advantagene – a start-up gene therapy company in Newton MA.
He is chairman of the Board of Cambridge in America, the representative body of the University and Colleges of Cambridge in North America. Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ’s College.

Jeremy Curnock-Cook

Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world. As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.
Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.

As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.

Founder and Managing Director of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.

Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia.

Jeremy received his MA in Natural Sciences from Trinity College in Dublin and was a research scientist at the Institute of Cancer Research from 1972 to 1973.

Alexander Crawford MA FCA

Alexander joined Calculus Capital in 2015 as an Investment Director, and has over 20 years’ investment and corporate finance -experience, including senior roles in JP Morgan and Evercore Partners in London, New York and Johannesburg. He has an MA in Mathematics from Cambridge University and qualified as a Chartered Accountant with KPMG.
Alexander joined Calculus Capital in 2015 as an Investment Director, and has over 20 years’ investment and corporate finance -experience, including senior roles in JP Morgan and Evercore Partners in London, New York and Johannesburg. He has an MA in Mathematics from Cambridge University and qualified as a Chartered Accountant with KPMG.

He manages a number of Calculus Capital’s unlisted and listed life sciences investments, including sitting as observer on the board of Synpromics, which creates synthetic promoters for gene therapies.  He also sits as director or observer on the boards of Blu Wireless Technology, Weeding Technologies and Every1Mobile.

Address

Arecor Limited,
Chesterford Research Park
Little Chesterford
CB10 1XL
United Kingdom

Telephone: +44 1223 426 060
Email: [email protected]

Address

Arecor Limited,
Chesterford Research Park
Little Chesterford
CB10 1XL
United Kingdom

Telephone: +44 1223 426 060
Email: [email protected]

View full ARECO profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.